Mannitolo Monico (Mannitol)

Mannitol increases plasma osmolality, creating an osmotic gradient that draws water from cells and interstitial spaces into the bloodstream. This expands plasma volume, enhances renal filtration, and leads to increased urinary excretion of water and electrolytes, thereby lowering pressure in the brain and eye.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goals. Mannitolo Monico is supplied as an injectable solution that must be prepared and administered according to the prescriber’s instructions.

Safety data for mannitol in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and use should only be considered if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the Mannitolo Monico product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mannitol is the most widely used osmotic diuretic for rapid pressure reduction. Compared with hypertonic saline, mannitol provides a predictable increase in plasma osmolality and a stronger diuretic effect, but may cause more pronounced electrolyte shifts. Choice of agent depends on the clinical scenario, patient tolerance and institutional protocols.

Mannitolo Monico should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the solution and avoid vigorous shaking. Before use, inspect the vial for particulate matter or discoloration and allow the product to reach room temperature if required for infusion.

The product is given as an intravenous infusion. The solution is diluted in an appropriate carrier fluid and infused over a period defined by the prescriber, typically ranging from a rapid bolus for emergency pressure reduction to a slower infusion for sustained diuresis. Administration must follow aseptic technique.

Serious adverse events include pulmonary edema, severe electrolyte disturbances such as hyperkalemia or hyponatremia, worsening renal failure, anaphylactoid reactions, hemolysis in patients with G6PD deficiency, and cardiac arrhythmias. Prompt monitoring of fluid balance, electrolytes and renal function is essential to detect these complications early.

Mannitolo Monico is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, severe pulmonary edema, or those with G6PD deficiency at risk of hemolysis. Caution is also advised in patients with renal impairment or electrolyte abnormalities.